drugset
drugset / Trial / NCT00234442

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

NCT00234442 ↗

Phase 2 Terminated 47 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

Timeline

Start
2004-07
Primary completion
—
Completion
2006-02

Outcome

Outcome not reported

Stopped (Enrollment): “Closed due to insufficient recruitment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — —

Indications

brain neoplasm non-small cell lung carcinoma